Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Vikas S. Sridhar, David Z.I. Cherney, Yuliya Lytvyn et al.|Hypertension|2025

Cited by 1